Drug Class: Angiogenesis and Growth Factor/ Receptor Inhibitors

Angiogenesis (and Growth Factor Receptor) Inhibitors: Multi-targeted RTK

Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment

Objective Response Rate (%)

Percentage of patients whose tumors shrink or go away after treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

2 Prior Therapies 3 Prior Therapies 4 Prior Therapies

Treatment given for recurrence occurring at any time after last platinum-based treatment

Objective Response Rate (%)

Percentage of patients whose tumors shrink or go away after treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

1 Prior Therapy Prior Therapies Not Reported

Angiogenesis (and Growth Factor Receptor) Inhibitors: Multi-targeted RTK

Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in NCCN Guidelines
NCT01047891 II Sorafenib, Topotecan A Randomized, Double-blind, Placebo Controlled, Multicenter Phase II Study to Assess the Efficacy and Safety of Sorafenib Added to Standard Treatment With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer

Sorafenib given with topotecan (5-day schedule) and continued as maintenance therapy results in a significant improvement in ORR, PFS and OS

ORR: 31 vs 12%*
PFS: 6.7 vs 4.4 months*
OS: 17.1 vs 10.1 months*

pub 2018

Drugs in Clinical Development
NCT03797326 II Pembrolizumab, Lenvatinib A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005)

Lenvatinib+pembrolizumab demonstrates encouraging efficacy and manageable safety in patients with heavily pretreated ovarian cancer, including those with prior platinum failure and those with previous bevacizumab exposure

ORR: 24%

abs Sep 2020

Retrospective Study: Pazopanib and Oral Cyclophosphamide II Cyclophosphamide, Pazopanib Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer

Pazopanib+cyclophosphamide is a well-tolerated regimen with clinically relevant benefit in patients with platinum-resistant or -refractory ovarian cancer

ORR: 45%
PFS: 5.5 months
OS: 9.5 months

pub 2020

NCT02788708 I Paclitaxel, Lenvatinib Phase I Evaluation of Lenvatinib and Weekly Paclitaxel in Patients With Recurrent Endometrial, Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Lenvatinib+weekly paclitaxel is tolerable with manageable side effects and shows promising response rates in platinum resistant ovarian cancer, also in patients with rare histologies

ORR: 71% (incl. 1 LGS, 2 clear cell, 1 carcinosarcoma)
PFS: 7.2 months

pub 2021

NCT03666143 I Tislelizumab, Sitravatinib A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors

Combination treatment with sitravatinib and tislelizumab is manageable and shows promising anti-tumor activity

ORR: 26%
PFS: 4.1 months

abs Apr 2021 and presentation

*Statistically significant result

Treatment given for recurrence occurring at any time after last platinum-based treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in NCCN Guidelines
NCT00281632 II Pazopanib Non-randomized, Open-label, Multi-center Phase II Study of GW786034 to Evaluate the Administration of Oral GW786034 in Subjects With Ovarian Cancer

Promising activity of single agent pazopanib

ORR: 17.6%

pub 2010

Drugs in Clinical Development
NCT01610206 II Gemcitabine, Pazopanib A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma

Paz+Gem vs Gem:

ORR: 20 vs 11%*
DCR: 80 vs 60%*
PFS: 5.3 vs 2.9 months

pub 2020

*Statistically significant result

< Return to Drug Classes

< Return to Clinical Trial Results Homepage